Crossmark

A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma with esophagogastric varices after progression on first-line lenvatinib combined with PD-1 inhibitor

Crossref DOI link: https://doi.org/10.1186/s12957-025-03742-0

Published Online: 2025-03-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Saifeng

Wen, Qin

Huang, Wenwu

Qiu, Zeyu

Feng, Long

Yi, Fengming
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82260130, 82260130, 82260130, 82260130, 82260130, 82260130)

Jiangxi Provincial Department of Science and Technology (20224BAB206021, 20224BAB206021, 20224BAB206021, 20224BAB206021, 20224BAB206021, 20224BAB206021)
License Information

Text and Data Mining valid from 2025-03-13

Version of Record valid from 2025-03-13
More Information

Article History

Received: 7 November 2024

Accepted: 7 March 2025

First Online: 13 March 2025

Declarations

:

: This study was approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University. Written informed consent was obtained from individual or guardian participants.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below